Title Slide

1
Title Slide
Clinical Cancer Research using Emerging Advanced
Technologies for Health
2
Breast Cancer Mortality in Women, 1951-2000
Lancet 365,1727,2005
3
The CREATE Health team
Proteomics
Genomics
Clinical Oncology
Tumour biology
Nano technology
Bioinformatics
Proteomics
4
Organisation
Scientific Secretary
CREATE Health Board Representatives from Lund
University and Industry
Director Carl Borrebaeck Deputy Carsten Rose
Financial Officer
Scientific Advisory Board
Steering Committee
IPR Review board
Administration
RNA/protein arrays C Borrebaeck
Proteomics P James
Bioinformatics C Peterson
DNA/RNA arrays Å Borg
Nano- technology T Laurell
Clinical Oncology C Rose
Tumor cell biology S Påhlman
J Häkkinen
J Vallon C Rovira

F Levander
G Marko-Varga J Nilsson
C Graffman M Ridderheim
H Axelson C Larsson
S Ek C Wingren
5
Localisation of BMC and USil
6
Localisation at the Biomedical Centre
You are here!
7
Mission and Vision Statements

• To create an integrative approach to solve
  complex
• clinical problems, by developing novel
  techniques -
• from bedside to bench and back again

• To create a substantial social impact for the
  patient
• through direct application of research for
  selection
• of an optimal, individually-based, cancer
  treatment

8
Research and Development

• Clinical focus
• To associate specific gene and/or protein
  signatures with
• Treatment-induced drug resistance
• Treatment response optimisation
• Tumour relapse survival time
• To identify novel targets for antibody-based
  therapy

9
CREATE Health Work flow
Clinic
CREATE Health Centre
Clinic
Sample handling
Technology development application
Diagnostics/Treatment
Data analysis mining
Sample storage tracking


Sample collection
Sample analysis
Treatment validation
Sample processning
Clinical transfer
Diagnostic validation
Technology development
Investigators Carl Borrebaeck Åke Borg Peter
James Thomas Laurell Carsten Peterson Sven
Påhlman Carsten Rose
10
Benefits for the patients

• Improved diagnosis
• Increased analytical sensitivity and capacity
• Improved prediction of disease progression
• Proteome-wide biomarker identification from fine
  needle/sure-cut biopsies
• Increased survival
• Disease stratification and tailoring of therapy
• Tumour specific antibodies for therapy

11
Discovery Projects

• Genomics focus
• define gene defects that are hereditary
• define chromosomal defects arising in cancer
• develop pathway focused gene monitoring methods
• find novel microRNA markers of cancer
• Proteomics focus
• discover protein markers of disease in cancer
  cells
• validate markers in serum for subsequent blood
  tests
• develop peptide monitoring for plasma analysis

12
Practical Application Projects

• Antibody microarrays
• antibody microarray based oncoproteomics
• nanostructured high performance chips for
  fluorescence/MS
• protein sampling in nanoscale for LCM single
  cell proteome
• Proteomic data basis tools
• BASE Proteios integrated algorithms for breast
  lymphomas
• Cell reconstruction validation

13
Principle of Antibody Microarrays
14
Practical ExamplePancreatic Adenocarcinomas
Healthy
Carcinoma

• Analysis of serum proteomes from 30 pancreatic
• carcinoma patients and
• 15 healthy individuals
• red - upregulated
• black - no change
• green - down regulated

100 Sensitivity 100 Specificity
15
Technology Transfer and Commercialisation
CREATE Health is actively engaged in developing
its discoveries to benefit society and has a
special board for IP issues. The CREATE Health
team has generated gt three world-wide
patents/year over the past five years, ranging
from basic research to applied biomedical
inventions As a result, six spin-off firms have
been created, some with gt 100 employees.
16
End Slide
www.createhealth.lth.se